Following are the day’s biggest winners and losers. Find out why shares of United Airlines and Smuckers popped while Tesoro and La-Z-Boy dropped.   Read More

Fund manager John Paulson made billions betting against subprime-backed securities. Should you trade in his wake?   Read More

In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?   Read More

Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.    Read More

Following are the day’s biggest winners and losers. Find out why shares of Domino’s and UPS popped while Vodaphone and SanDisk dropped.   Read More

So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.   Read More

FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."    Read More

Sometimes a deal from hell can become one hell of a deal. Following are three takeover stories that could be worth a trade.   Read More

The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"   Read More

The Lightning Round is extended in this new CNBC.com exclusive feature.   Read More